{"id":48077,"date":"2022-09-07T20:01:51","date_gmt":"2022-09-07T18:01:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/"},"modified":"2022-09-07T20:01:51","modified_gmt":"2022-09-07T18:01:51","slug":"harris-williams-advises-jordi-labs-on-its-sale-to-rqm","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/","title":{"rendered":"Harris Williams Advises Jordi Labs on its Sale to RQM+"},"content":{"rendered":"
\n

RICHMOND, Va.–(BUSINESS WIRE)–Harris Williams<\/a>, a global investment bank specializing in M&A advisory services, announces it advised Jordi Labs on its sale to RQM+, a portfolio company of Linden Capital Partners (Linden). Jordi Labs provides a full suite of regulatory, investigative and other related analytical chemistry testing services primarily to medical device manufacturers. The transaction was led by Paul Hepper<\/a>, Nick Owens<\/a>, Cameron Thomas<\/a> and Bethel Hailemichael of the Harris Williams Healthcare & Life Sciences (HCLS) Group<\/a>.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are thrilled to have represented Jordi Labs and believe the company is well-positioned to benefit from the growth in outsourced testing services from medical device OEMs who face increasing regulatory demands,\u201d said Paul Hepper, a managing director at Harris Williams. \u201cHarris Williams has a track record of representing best-in-class, market-leading businesses, like Jordi Labs, that provide mission critical services to medical device manufacturers.\u201d\n<\/p>\n

\n\u201cIt was a pleasure working with President Dr. Mark Jordi, Vice President Patrick Burke and the rest of the Jordi Labs team,\u201d added Nick Owens, a director at Harris Williams. \u201cJordi Labs has thrived under the stewardship of the Jordi family, and we believe the combination with RQM+ will create significant synergies to help accelerate growth of the combined platform.\u201d\n<\/p>\n

\nJordi Labs was founded in 1980 and provides the highest quality analytical testing services to the medical device, pharmaceutical, and other industries, with a special emphasis on chemical identification and material solutions. Jordi\u2019s goal is to help its customers overcome their analytical challenges by providing excellent service from its highly trained staff. The company\u2019s proprietary technology and testing techniques differentiate it from competitors and enable Jordi Labs to solve the most critical, complex issues faced by its customers.\n<\/p>\n

\nRQM+ is the leading MedTech service provider with the world\u2019s largest global team of regulatory and quality experts. The company provides comprehensive regulatory, quality, clinical, and laboratory services, supporting market access throughout the entire product lifecycle for medical devices and diagnostics. With more former FDA, MHRA, and notified body regulators than any other firm, the RQM+ team has deep expertise in all clinical specialties. RQM+ currently works for eight of the top 10 medical device manufacturers and seven of the top 10 IVD companies.\n<\/p>\n

\nLinden is a Chicago-based private equity firm focused exclusively on the healthcare industry. Founded in 2004, Linden is one of the country\u2019s largest dedicated healthcare private equity firms. Linden\u2019s strategy is based upon three elements: (i) healthcare specialization, (ii) integrated private equity and operating expertise, and (iii) its differentiated human capital program. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical and services segments of healthcare. Since its founding, Linden has invested in over 45 healthcare companies encompassing over 250 total transactions. The firm has raised over $6.5 billion in limited partner commitments since inception.\n<\/p>\n

\nHarris Williams<\/a>, an investment bank specializing in M&A advisory services, advocates for sellers and buyers of companies worldwide through critical milestones and provides thoughtful advice during the lives of their businesses. By collaborating as one firm across Industry Groups and geographies, the firm helps its clients achieve outcomes that support their objectives and strategically create value. Harris Williams is committed to execution excellence and to building enduring, valued relationships that are based on mutual trust. Harris Williams is a subsidiary of the PNC Financial Services Group, Inc. (NYSE: PNC).\n<\/p>\n

\nThe Harris Williams HCLS Group has experience across a broad range of sectors, including healthcare providers; payors and payor services; outsourced pharmaceutical services; medical device supply chain; healthcare IT; and pharmacy. For more information on the HCLS Group and other recent transactions, visit the HCLS Group\u2019s<\/a> section of the Harris Williams website.\n<\/p>\n

\nHarris Williams LLC is a registered broker-dealer and member of FINRA and SIPC. Harris Williams & Co. Ltd is a private limited company incorporated under English law with its registered office at 8th Floor, 20 Farringdon Street, London EC4A 4AB, UK, registered with the Registrar of Companies for England and Wales (registration number 07078852). Harris Williams & Co. Ltd is authorized and regulated by the Financial Conduct Authority. Harris Williams & Co. Corporate Finance Advisors GmbH is registered in the commercial register of the local court of Frankfurt am Main, Germany, under HRB 107540. The registered address is Bockenheimer Landstrasse 33-35, 60325 Frankfurt am Main, Germany (email address: hwgermany@harriswilliams.com<\/a>). Gesch\u00e4ftsf\u00fchrer\/Directors: Jeffery H. Perkins, Paul Poggi. (VAT No. DE321666994). Harris Williams is a trade name under which Harris Williams LLC, Harris Williams & Co. Ltd and Harris Williams & Co. Corporate Finance Advisors GmbH conduct business.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor media inquiries, please contact Julia Moore at media@harriswilliams.com<\/a>.\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

RICHMOND, Va.–(BUSINESS WIRE)–Harris Williams, a global investment bank specializing in M&A advisory services, announces it advised Jordi Labs on its sale to RQM+, a portfolio company of Linden Capital Partners (Linden). Jordi Labs provides a full suite of regulatory, investigative and other related analytical chemistry testing services primarily to medical device manufacturers. The transaction was … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48077","6":"format-standard","7":"category-industry"},"yoast_head":"\nHarris Williams Advises Jordi Labs on its Sale to RQM+ - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harris Williams Advises Jordi Labs on its Sale to RQM+ - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"RICHMOND, Va.–(BUSINESS WIRE)–Harris Williams, a global investment bank specializing in M&A advisory services, announces it advised Jordi Labs on its sale to RQM+, a portfolio company of Linden Capital Partners (Linden). Jordi Labs provides a full suite of regulatory, investigative and other related analytical chemistry testing services primarily to medical device manufacturers. The transaction was ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-07T18:01:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220907006154\/en\/683130\/21\/HW_Logo_HorizontalColor.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Harris Williams Advises Jordi Labs on its Sale to RQM+\",\"datePublished\":\"2022-09-07T18:01:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\\\/\"},\"wordCount\":777,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220907006154\\\/en\\\/683130\\\/21\\\/HW_Logo_HorizontalColor.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\\\/\",\"name\":\"Harris Williams Advises Jordi Labs on its Sale to RQM+ - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220907006154\\\/en\\\/683130\\\/21\\\/HW_Logo_HorizontalColor.jpg\",\"datePublished\":\"2022-09-07T18:01:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220907006154\\\/en\\\/683130\\\/21\\\/HW_Logo_HorizontalColor.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220907006154\\\/en\\\/683130\\\/21\\\/HW_Logo_HorizontalColor.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harris Williams Advises Jordi Labs on its Sale to RQM+\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Harris Williams Advises Jordi Labs on its Sale to RQM+ - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/","og_locale":"en_US","og_type":"article","og_title":"Harris Williams Advises Jordi Labs on its Sale to RQM+ - Pharma Trend","og_description":"RICHMOND, Va.–(BUSINESS WIRE)–Harris Williams, a global investment bank specializing in M&A advisory services, announces it advised Jordi Labs on its sale to RQM+, a portfolio company of Linden Capital Partners (Linden). Jordi Labs provides a full suite of regulatory, investigative and other related analytical chemistry testing services primarily to medical device manufacturers. The transaction was ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-07T18:01:51+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220907006154\/en\/683130\/21\/HW_Logo_HorizontalColor.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Harris Williams Advises Jordi Labs on its Sale to RQM+","datePublished":"2022-09-07T18:01:51+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/"},"wordCount":777,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220907006154\/en\/683130\/21\/HW_Logo_HorizontalColor.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/","url":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/","name":"Harris Williams Advises Jordi Labs on its Sale to RQM+ - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220907006154\/en\/683130\/21\/HW_Logo_HorizontalColor.jpg","datePublished":"2022-09-07T18:01:51+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220907006154\/en\/683130\/21\/HW_Logo_HorizontalColor.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220907006154\/en\/683130\/21\/HW_Logo_HorizontalColor.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/harris-williams-advises-jordi-labs-on-its-sale-to-rqm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Harris Williams Advises Jordi Labs on its Sale to RQM+"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48077"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48077\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}